Matricelf gets FDA feedback for proposed NewRal spinal cord trial elements
FDA feedback supports Matricelf’s proposed patient population, single-arm open-label trial design, primary safety assessments and exploratory efficacy measures as it prepares for a future IND submission for NewRal.
FDA feedback supports the proposed patient population, single arm open label trial design, primary safety assessments and exploratory efficacy measuresWritten regulatory feedback provides guidance as Matricelf advances preparations toward a future IND submission for NewRalNESS ZIONA, Israel, Sept…